Methimazole-induced remission rates in pediatric Graves’ disease: a systematic review

Objective Comparison of studies on remission rates in pediatric Graves’ disease is complicated by lack uniformity treatment protocols, definition, and follow-up duration. We performed a systematic review attempted to create recalculating based an intention-to-treat analysis. Methods PubMed Embase were searched August 2020 for patients with disease: (i) 2 18 years age, (ii) initially treated methimazole or carbimazole at least months, (iii) duration 1 year after cessation carbimazole. All reported recalculated using Results Of 1890 articles, 29 articles consisting 24 patient cohorts included total 3057 (82.6% female). Methimazole was prescribed 2864 (93.7%). Recalculation analysis resulted overall rate 28.8% (829/2880). Pooled 23.7, 31.0, 43.7, 75% respectively 1.5–2.5 years, 2.5–5 5–6 (two studies), 9 (single study) The occurrence adverse events 419 2377 (17.6%), major side effects 25 (1.1%). Conclusions Using standardized calculation, the methimazole-treated GD 28.8%. A few small indicate that longer increases rate. However, evidence limited further research necessary investigate efficacy durations.